Occult metastasis

D. Hawes, A. Munro Neville, Richard J Cote

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The most important factor affecting the outcome of patients with invasive cancers is whether the tumor has spread, either regionally (to regional lymph nodes) or systemically. However, a proportion of patients with no evidence of systemic dissemination will develop recurrent disease after primary 'curative' therapy. Clearly, these patients had occult systemic spread of disease that was undetectable by methods routinely employed (careful pathological, clinical, biochemical and radiological evaluation). In addition, the success of adjuvant therapy is assumed to stem from its ability to eradicate occult metastases before they become clinically evident [1]. Therefore, methods for the detection of occult metastases in patients with the earliest stage of cancer, i.e., prior to detection of metastases by any other clinical or pathological analysis, have received a great deal of attention.

Original languageEnglish
Pages (from-to)229-242
Number of pages14
JournalBiomedicine and Pharmacotherapy
Volume55
Issue number4
DOIs
StatePublished - May 1 2001
Externally publishedYes

Fingerprint

Neoplasm Metastasis
Neoplasms
Lymph Nodes
Therapeutics

Keywords

  • Bone marrow
  • Immunohistochemistry
  • Lymph nodes
  • Micrometastasis
  • Occult metastasis
  • Prognostic significance
  • RT-PCR

ASJC Scopus subject areas

  • Pharmacology

Cite this

Occult metastasis. / Hawes, D.; Munro Neville, A.; Cote, Richard J.

In: Biomedicine and Pharmacotherapy, Vol. 55, No. 4, 01.05.2001, p. 229-242.

Research output: Contribution to journalArticle

Hawes, D. ; Munro Neville, A. ; Cote, Richard J. / Occult metastasis. In: Biomedicine and Pharmacotherapy. 2001 ; Vol. 55, No. 4. pp. 229-242.
@article{02dd7f162a6f40558fc0598572ab5fc2,
title = "Occult metastasis",
abstract = "The most important factor affecting the outcome of patients with invasive cancers is whether the tumor has spread, either regionally (to regional lymph nodes) or systemically. However, a proportion of patients with no evidence of systemic dissemination will develop recurrent disease after primary 'curative' therapy. Clearly, these patients had occult systemic spread of disease that was undetectable by methods routinely employed (careful pathological, clinical, biochemical and radiological evaluation). In addition, the success of adjuvant therapy is assumed to stem from its ability to eradicate occult metastases before they become clinically evident [1]. Therefore, methods for the detection of occult metastases in patients with the earliest stage of cancer, i.e., prior to detection of metastases by any other clinical or pathological analysis, have received a great deal of attention.",
keywords = "Bone marrow, Immunohistochemistry, Lymph nodes, Micrometastasis, Occult metastasis, Prognostic significance, RT-PCR",
author = "D. Hawes and {Munro Neville}, A. and Cote, {Richard J}",
year = "2001",
month = "5",
day = "1",
doi = "10.1016/S0753-3322(01)00052-X",
language = "English",
volume = "55",
pages = "229--242",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson",
number = "4",

}

TY - JOUR

T1 - Occult metastasis

AU - Hawes, D.

AU - Munro Neville, A.

AU - Cote, Richard J

PY - 2001/5/1

Y1 - 2001/5/1

N2 - The most important factor affecting the outcome of patients with invasive cancers is whether the tumor has spread, either regionally (to regional lymph nodes) or systemically. However, a proportion of patients with no evidence of systemic dissemination will develop recurrent disease after primary 'curative' therapy. Clearly, these patients had occult systemic spread of disease that was undetectable by methods routinely employed (careful pathological, clinical, biochemical and radiological evaluation). In addition, the success of adjuvant therapy is assumed to stem from its ability to eradicate occult metastases before they become clinically evident [1]. Therefore, methods for the detection of occult metastases in patients with the earliest stage of cancer, i.e., prior to detection of metastases by any other clinical or pathological analysis, have received a great deal of attention.

AB - The most important factor affecting the outcome of patients with invasive cancers is whether the tumor has spread, either regionally (to regional lymph nodes) or systemically. However, a proportion of patients with no evidence of systemic dissemination will develop recurrent disease after primary 'curative' therapy. Clearly, these patients had occult systemic spread of disease that was undetectable by methods routinely employed (careful pathological, clinical, biochemical and radiological evaluation). In addition, the success of adjuvant therapy is assumed to stem from its ability to eradicate occult metastases before they become clinically evident [1]. Therefore, methods for the detection of occult metastases in patients with the earliest stage of cancer, i.e., prior to detection of metastases by any other clinical or pathological analysis, have received a great deal of attention.

KW - Bone marrow

KW - Immunohistochemistry

KW - Lymph nodes

KW - Micrometastasis

KW - Occult metastasis

KW - Prognostic significance

KW - RT-PCR

UR - http://www.scopus.com/inward/record.url?scp=0035015073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035015073&partnerID=8YFLogxK

U2 - 10.1016/S0753-3322(01)00052-X

DO - 10.1016/S0753-3322(01)00052-X

M3 - Article

C2 - 11393810

AN - SCOPUS:0035015073

VL - 55

SP - 229

EP - 242

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 4

ER -